TAVR: Reasons to Consider Mitral Annular Calcification

Courtesy of Dr. Carlos Fava.

TAVR: Reasons to Consider Mitral Annular CalcificationAortic valve calcification and mitral annular calcification have the same etiology and are frequently present in high-risk patients undergoing transcatheter aortic valve replacement (TAVR). The implications of mitral annular calcification for patients undergoing TAVR has not been entirely clarified yet.

 

The study examined 782 patients with severe aortic stenosis who underwent TAVR. Among these patients, 375 (49.9%) presented mitral annular calcification in the computerized tomography scan:

  • Mild: 30.4%
  • Moderate: 9.5%
  • Severe: 9.5%

 

Patients who experienced the highest rate of mitral annular calcification were the eldest (83 vs. 81.9 years old), those with chronic renal insufficiency, and those with a higher Society of Thoracic Surgeons (STS) score (8.8 vs. 7.5; p <0,001).

 

Procedural success was similar for all patients, and no differences in mortality and major complications were observed at 30 daysAt 1 year, severe mitral annular calcification was found to be an independent predictor of all-cause mortality (hazard ratio [HR]: 1.95; 95% confidence interval [CI]: 1.24-3.07; p = 0.004) and cardiovascular mortality (HR: 2.35; 95% CI: 1.19-4.66; p = 0.01). Furthermore, it was an independent predictor of the need for a new permanent pacemaker after TAVR (odds ratio [OR]: 2.83; 95% CI: 1.08-7.47; p = 0.03).

 

Conclusion

Half of the patients with severe aortic stenosis experience mitral annular calcification. Severe mitral annular calcification is associated with increased all-cause and cardiovascular mortality, and with conduction disorders after TAVR. This pathology should be included in future risk stratification models.

 

Courtesy of Dr. Carlos Fava. Buenos Aires Favaloro Foundation, Argentina.

 

Original title: Concomitant Mitral Annular Calcification and Severe Aortic Stenosis: Prevalence, Characteristics and Outcome Following Transcatheter Aortic Valve Replacement.

Reference: Yigal Abramowitz, et al. European Heart Journal Advance Access published December 30, 2016.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....